Details of the Drug | DrugMAP

General Information of Drug (ID: DMYW8UN)

Drug Name

MMR

Indication

Disease Entry	ICD 11	Status	REF
Measles	1F03	Phase 3	[1]
Mumps virus infection	1D80	Phase 3	[1]
Rubella prophylaxis	1F02	Phase 3	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C16H32N6O4S2
Canonical SMILES: CSCCC(C(=O)NC(CCSC)C(=O)NC(CCCN=C(N)N)C(=O)O)N
InChI: 1S/C16H32N6O4S2/c1-27-8-5-10(17)13(23)21-11(6-9-28-2)14(24)22-12(15(25)26)4-3-7-20-16(18)19/h10-12H,3-9,17H2,1-2H3,(H,21,23)(H,22,24)(H,25,26)(H4,18,19,20)
InChIKey: OXIWIYOJVNOKOV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 18222907
TTD ID: D04VRN

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT02184572) Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine inHealthy Children 12 to 15 Months of Age. U.S. National Institutes of Health.